 | |
| Clinical data | |
|---|---|
| Trade names | Dynocard |
| Other names | Gitoxin 3′,3′,3′′′,4′′′′,16-pentaformate |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| ECHA InfoCard | 100.030.397 |
| Chemical and physical data | |
| Formula | C46H64O19 |
| Molar mass | 920.999 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Gitoformate (INN, or pentaformylgitoxin, trade name Dynocard) is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat).[1] Produced by Madaus, it is not available in the US, and does not seem to be available in Europe either.
Chemistry
Gitoformate is a derivative of the glycoside gitoxin, with five of the six free hydroxyl groups formylated, one on the aglycon and four on the sugar.[2][3] Gitoxin, a cardiac glycoside from the woolly foxglove (Digitalis lanata), has an aglycon of the cardenolide type named gitoxigenin, which is also the aglycon of lanatoside B, another Digitalis lanata glycoside.[4]
References
- ^ Rietbrock N, Woodcock BG, Hrazdil U (1984). "[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]". Arzneimittel-Forschung. 34 (8): 915–917. PMID 6541927.
- ^ Dei Cas L, Affatato A, Buia E, Casciarri G, Faggiano P, Giunti G, et al. (1984). "[Plasma levels of gitoxin (by RIA and rubidium-86 uptake) and systolic time after treatment with a single dose of gitoformate]". Cardiologia. 29 (5–6): 291–300. PMID 6542412.
- ^ "Gitoxin". PubChem. U.S. National Library of Medicine.
- ^ Foye WO, Lemke TL, Williams DA (2008). Foye's principles of medicinal chemistry. Lippincott Williams & Wilkins. p. 699. ISBN 978-0-7817-6879-5.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 12 March 2024, at 01:46